EP1978827A1 - Nahrungsergänzungsmittel auf basis von vitaminen der b-gruppe, spurenelementen und omega-3- und/oder -6-fettsäuren, und verwendung dieses nahrungsergänzungsmittels bei der gleichzeitigen behandlung von lokalisierter cellulite und nachlassen der hautelastizität - Google Patents

Nahrungsergänzungsmittel auf basis von vitaminen der b-gruppe, spurenelementen und omega-3- und/oder -6-fettsäuren, und verwendung dieses nahrungsergänzungsmittels bei der gleichzeitigen behandlung von lokalisierter cellulite und nachlassen der hautelastizität

Info

Publication number
EP1978827A1
EP1978827A1 EP06830661A EP06830661A EP1978827A1 EP 1978827 A1 EP1978827 A1 EP 1978827A1 EP 06830661 A EP06830661 A EP 06830661A EP 06830661 A EP06830661 A EP 06830661A EP 1978827 A1 EP1978827 A1 EP 1978827A1
Authority
EP
European Patent Office
Prior art keywords
group
vitamins
fatty acids
trace elements
zinc
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Withdrawn
Application number
EP06830661A
Other languages
English (en)
French (fr)
Inventor
Philippe Msika
Nathalie Piccardi
Pascale Cochet
Michel Moreau
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Laboratoires Expanscience SA
Original Assignee
Laboratoires Expanscience SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Laboratoires Expanscience SA filed Critical Laboratoires Expanscience SA
Publication of EP1978827A1 publication Critical patent/EP1978827A1/de
Withdrawn legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/115—Fatty acids or derivatives thereof; Fats or oils
    • A23L33/12—Fatty acids or derivatives thereof
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/15—Vitamins
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
    • A23L33/16—Inorganic salts, minerals or trace elements
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
    • A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
    • A23L33/30—Dietetic or nutritional methods, e.g. for losing weight
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/075—Ethers or acetals
    • A61K31/08—Ethers or acetals acyclic, e.g. paraformaldehyde
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/201—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having one or two double bonds, e.g. oleic, linoleic acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/202—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids having three or more double bonds, e.g. linolenic
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/04—Sulfur, selenium or tellurium; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/06—Aluminium, calcium or magnesium; Compounds thereof, e.g. clay
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/26—Iron; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/30—Zinc; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/32—Manganese; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K33/00—Medicinal preparations containing inorganic active ingredients
    • A61K33/24—Heavy metals; Compounds thereof
    • A61K33/34—Copper; Compounds thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P3/00—Drugs for disorders of the metabolism
    • A61P3/04—Anorexiants; Antiobesity agents
    • A—HUMAN NECESSITIES
    • A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
    • A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
    • A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs

Definitions

  • the invention relates to the use of a mixture of trace elements and vitamins of group B, administered orally, for the simultaneous treatment of cellulite and localized skin loosening.
  • the invention also relates to a method of cosmetic treatment, orally, overweight localized in a superficial area and simultaneously cutaneous relaxation in the same localized area.
  • the invention also relates to a dietary supplement, which may be administered in the context of said use or of said cosmetic treatment method.
  • adipose tissue represents 20 to 30% of body weight in women and 10 to 15% in men.
  • Subcutaneous fat is twice as thick in women than in men.
  • fats accumulate around and above the girdle (android metabolic risk factor distribution) and below the girdle, in the glutofemoral region in women (gynoid distribution, uncorrelated to vascular risk).
  • One of the characteristics of this fat accumulated in the lower body is to be difficult to mobilize. It is intended to ensure the energy needs of reproduction (pregnancy and, especially, breastfeeding) and is thus the most important energy reservoir of the body.
  • the adipocytes are spherical cells are the intracellular space is filled by a large vacuole filled with triglycerides. Adipocytes can change rapidly. Indeed, these cells can reach, depending on circumstances, 40 ⁇ m to 120 ⁇ m in diameter, which corresponds to an increase of 27 times in volume. In some extreme cases, this increase can be up to 40 times.
  • the adipocyte is the main energetic actor of the body since it is able to store (capture or lipogenesis) or, conversely, to mobilize (lipolysis) rapidly triglycerides, major energy sources of the body.
  • Lipogenesis involves the synthesis of triacylglycerols which results from the esterification of the glycerol 1-3-phosphate by the activated fatty acids; conversely, lipolysis corresponds to the hydrolysis of stored triacylglycerols, glycerol and fatty acids.
  • Different mechanisms have been brought to light, which control lipolysis and lipogenesis, which involve, for example, receptors such as alpha-2 and / or beta-1 and -2 receptors, Al-type adenosine receptors, prostaglandin E2, YY type YY and neuropeptide NPY, but also sex hormones.
  • lipolytics acting on the elimination of lipid overloads
  • liporeducing agents fight against the formation of fats
  • Caffeine which is found in many plants: green tea, guarana seeds: inhibits phosphodiesterase, thus ensuring optimal intracellular cAMP levels, stimulates ⁇ receptors and inhibits lipoprotein lipase; > Rhodysterol (extract of a red algae): activates the ⁇ receptors and promotes the penetration of caffeine;
  • Palmitoyl-carnitine accelerates the combustion of fatty acids, improving their uptake by mitochondria;
  • the alpha and gamma bioactives (derived respectively from a marine bacterium and a fungus): block the ⁇ 2 and NPY receptors;
  • Rutin (extracted from Ruta graveolens): isolates glucose and prevents its association with free fatty acids.
  • formulations comprising these known slimming active agents can be supplemented by restructuring and smoothing active ingredients which make it possible to combat the loosening of the skin.
  • the slimming active agents of the prior art are most often administered topically.
  • Dietary supplements comprising a combination of vitamins, trace elements and essential fatty acids are already known in the prior art.
  • International Application WO 91/11117 discloses an orally administered formulation containing vitamins (B1, B2, B3, B5, B6, B8, B9, B12, C, D3, K1) and minerals (boron, calcium, chromium, copper, iodine, iron, magnesium, manganese, molybdenum, potassium, selenium, silica, vanadium and zinc) in combination with antioxidants and fish oils.
  • vitamins B1, B2, B3, B5, B6, B8, B9, B12, C, D3, K1
  • minerals boron, calcium, chromium, copper, iodine, iron, magnesium, manganese, molybdenum, potassium, selenium, silica, vanadium and zinc
  • US Pat. No. 6,071,544 describes the use of en-3 or ⁇ -6 fatty acids, to promote weight loss in cats, in an oral composition, comprising in combination vitamins (A, B1, B2, B3, B5, B6, B7, B8, B9, B12, C, D3 and E) and minerals (calcium, cobalt, copper, iron, magnesium, manganese, phosphorus, potassium, selenium and zinc). No effect on sagging skin is noted.
  • the invention firstly relates to the use of an association comprising:
  • At least one trace element, in salt or complex form selected from the group consisting of zinc, magnesium, copper, selenium, chromium, iron, manganese and their mixtures;
  • At least one vegetable and / or animal oil comprising at least one essential fatty acid chosen from acides-3 fatty acids and ⁇ -6 fatty acids;
  • the subject of the invention is also a cosmetic treatment method for overweight localized in a superficial zone and simultaneously cutaneous relaxation in this same localized zone, comprising the oral administration of an association comprising:
  • At least one trace element, in salt or complex form selected from the group consisting of zinc, magnesium, copper, selenium, chromium, iron, manganese and their mixtures; at least one vegetable and / or animal oil comprising at least one essential fatty acid chosen from acides-3 fatty acids and ⁇ -6 fatty acids;
  • the invention finally relates to a dietary supplement, intended for oral administration, consisting of an association consisting of: a) a mixture of vitamins of group B and their derivatives; b) at least one salt or complex of a trace element, said trace element being selected from the group consisting of zinc, magnesium, copper, selenium, chromium, iron, manganese and mixtures thereof; c) at least one vegetable and / or animal oil comprising at least one essential fatty acid chosen from en-3 and / or ⁇ -6 fatty acids; d) if appropriate, a plant enzyme advantageously chosen from the group comprising papain, bromelain and ficine; e) and at least one excipient suitable for oral administration.
  • the vitamins present in the food supplement according to the invention are exclusively vitamins of group B.
  • the mass ratios are determined, unless otherwise indicated, on the basis of the specific weight of the compounds (fatty acids, vitamins, trace element) alone.
  • trace elements it is based on the weight of the trace element alone and not on the weight of its salt or complex (for example, weight of zinc in zinc sulphate).
  • vitamins is based on the weight of vitamin contained in the derivative (for example, weight of vitamin B3 contained in commercial nicotinamide).
  • essential en-3 and ⁇ -6 fatty acids their content is based on vegetable and / or animal oils.
  • the combination or the dietary supplement advantageously comprises said vitamins, said trace elements and said essential fatty acids in a mass ratio.
  • said essential fatty acids in ⁇ -3 and in ⁇ -6 are advantageously present in a mass ratio ⁇ -3: ⁇ -6 of between 1 and 5, advantageously 1 and 4, more advantageously 1 and 3, still more preferably between 1.4 and 2.1. This ratio is advantageously about 2.
  • the combination or the dietary supplement advantageously comprises said vitamins and said trace elements in a mass ratio (vitamins of group B): (trace elements) between 0.2 and 1, advantageously between 0.4 and 0.6.
  • This mass ratio is preferably about 0.5.
  • the acides-3 essential fatty acids present in the combination or in the food supplement are advantageously eicosapentaenoic acid (EPA) and / or docosahéxaenoic acid (DHA).
  • EPA eicosapentaenoic acid
  • DHA docosahéxaenoic acid
  • the combination or the dietary supplement advantageously comprises more EPA than DHA, more advantageously at least 2 times more, better at least 3 times more, still more preferably at least 4 times more, or even at least 5 times more, EPA than DHA.
  • the acides-6 essential fatty acids present in the combination or in the dietary supplement are advantageously linoleic acid and / or gamma-linolenic acid.
  • the combination or the dietary supplement advantageously comprises more linoleic acid than gamma-linolenic acid, more advantageously the mass ratio linoleic acid: gamma-linolenic acid is between 1.2 and 2, more advantageously between 1.6 and 1.9.
  • the vitamins of group B are advantageously chosen from the group consisting of vitamins B2, B3, B5, B6, B8, B9, B12 and mixtures thereof. The sources of these vitamins are advantageously:
  • nicotinic acid nicotinamide - vitamin B5 (pantothenic acid): calcium D-pantothenate, sodium D-pantothenate, dexpantothenol
  • vitamin B9 folic acid
  • folic acid - vitamin B 12 cobalamines
  • Group B vitamins and their derivatives are advantageously selected from the group consisting of riboflavin, nicotinamide, calcium pantothenate, pyridoxine hydrochloride, biotin, folic acid, cobalamines, and mixtures thereof.
  • the zinc is advantageously in the form of a zinc salt or in the form of a complex, in particular in the form of zinc acetate, zinc chloride, zinc citrate, zinc gluconate, zinc lactate, zinc oxide, zinc carbonate or zinc sulphate.
  • zinc is introduced in the form of zinc sulphate.
  • the food supplement according to the invention then advantageously comprises 15 to 25 mg, per dose, of zinc sulphate.
  • Magnesium makes it possible to convert the vitamins of the B group into an active form. It is advantageously introduced into the combination or the food supplement in the form of magnesium acetate, magnesium carbonate, magnesium chloride, magnesium salts of citric acid, magnesium gluconate, magnesium glycerophosphate, magnesium salts of orthophosphoric acid, magnesium lactate, magnesium hydroxide, magnesium oxide or magnesium sulfate, magnesium is preferably introduced in the form of magnesium oxide.
  • the food supplement according to the invention then advantageously comprises 30 to 35 mg, per dose, of magnesium oxide.
  • the copper is advantageously introduced into the combination or the food supplement in the form of copper carbonate, copper citrate, copper gluconate, copper sulphate or copper-lysine complex.
  • the selenium is advantageously introduced into the combination or the dietary supplement in the form of selenium-fed yeast extracts, sodium selenate, sodium hydrogenoselenite or sodium selenite.
  • Chromium is advantageously introduced into the combination or the dietary supplement in the form of chromium (III) chloride or of chromium (III) sulphate.
  • Iron is advantageously introduced into the combination or the food supplement in the form of ferrous carbonate, ferrous citrate, ferric ammonium citrate, ferrous gluconate, ferrous fumarate, sodium ferric diphosphate, ferrous lactate, sulphate ferric diphosphate (ferric pyrophosphate) or ferric saccharate.
  • Manganese is advantageously introduced into the combination in the form of manganese carbonate, manganese chloride, manganese citrate, manganese gluconate, manganese glycerophosphate or manganese sulfate.
  • the association or the dietary supplement preferably comprises at least zinc and magnesium, as trace elements; according to an advantageous variant of the invention, the only trace elements present in the combination or the food supplement are zinc and magnesium.
  • oils used in the combination or dietary supplement are oils rich in omega-3 (nuts, rapeseed, wheat germ, soya, canola, flax, fish, krill) and / or omega-6 (grape seed, black currant, sunflower, nut, corn, borage, evening primrose, safflower, wheat germ, soybean, sesame, rapeseed, peanut oil) , nutty, olive).
  • omega-3 nuts, rapeseed, wheat germ, soya, canola, flax, fish, krill
  • omega-6 sea seed, black currant, sunflower, nut, corn, borage, evening primrose, safflower, wheat germ, soybean, sesame, rapeseed, peanut oil
  • the oils advantageously used in the context of the invention are borage oil and / or fish oil.
  • the association or the food supplement further comprises a plant enzyme, in particular a plant enzyme chosen from the group consisting of papain, bromelain and ficine.
  • the food supplement according to the invention advantageously consists of a mixture of 365 mg consisting of: a) 15 to 30 mg of a mixture of vitamins of group B and their derivatives selected from the group consisting of riboflavin, nicotinamide calcium pantothenate, pyridoxine hydrochloride, biotin, folic acid, and cobalamines; (b) 38 to 61 mg of a mixture of magnesium oxide and zinc sulphate; c) 200 to 245 mg of a mixture of borage oil and fish oil; d) 20 to 30 mg of a pineapple extract titrated with bromelain, and e) a suitable excipient (s) for oral administration.
  • excipients which can conventionally be used are glyceryl monostearate, rapeseed or soy lecithin, vegetable oils (soya, sunflower), hydrogenated or partially hydrogenated vegetable oils, and waxes such as beeswax.
  • the cosmetic treatment method according to the invention can be particularly advantageous in pregnant women or women who have given birth for less than 6 months, who can breastfeed.
  • the present invention thus also relates to a cosmetic treatment method for combating overweight localized in a superficial area and simultaneously to fight against sagging skin in this same area located in pregnant women or women having given birth for less than 6 years. month (who can breastfeed).
  • one of the advantages of the combination according to the invention is the absence of active principle against indicated in the woman having given birth, especially in the woman who is breastfeeding.
  • the combination or dietary supplement can provide the woman who has just given birth to group B vitamins, breastfeeding or pregnant women who may be considered a group at risk of vitamin B deficiency, in particular of vitamins B2, B5, B6 and B9.
  • the term “thinning” or “fight against localized excess weight” is meant according to the present invention an action to avoid or at least reduce the formation of subcutaneous fat as described above. Thus, it significantly limits the storage of fat (lipogenesis) and / or significantly stimulates the destocking of fat (lipolysis). This action is in favor of a reduction of adipose tissue and is reflected in particular by a decrease in overloads or unsightly reserves, by a refinement of the silhouette, by an acceleration of the elimination of surpluses, by a better definition of the body contour. or a reshaped silhouette.
  • the term "cosmetic treatment for combating localized overweight and localized skin loosening" is intended to mean the use of a cosmetic treatment that makes it possible to visibly measure the action described above.
  • the combination or the food supplement according to the invention can be used for the treatment of areas of the skin likely to form these localized weight overloads, namely areas where these overloads are already formed or in training courses.
  • the different compounds of the combination can be administered simultaneously (in the same capsule for example) or as combination products for separate use or spread over time.
  • the various compounds of the combination are advantageously administered simultaneously (in the same capsule for example).
  • the dietary supplement or combination is formulated to be administered orally. It can thus be in the form of capsule, capsule, tablet, granule, advantageously in the form of capsule.
  • the envelope of these soft capsules or capsules may contain in particular animal gelatin such as fish gelatin, glycerine, or a material of plant origin such as a cellulose or starch derivative, or a vegetable protein.
  • the mixture of active ingredients may be attached to a powdery carrier such as silica, cellulose, and maltodextrin.
  • the instructions for use are 2 doses per day.
  • the dietary supplement according to the present invention may advantageously comprise any suitable vehicle or excipient, acceptable from a nutraceutical point of view, as well as conventional additives, known to those skilled in the art.
  • the dietary supplement and the combination may be used in combination with other slimming active agents such as lipolytics and liporeducing agents simultaneously, separately or spread over time.
  • the slimming active agent of the lipolytic type can be chosen from: caffeine, rhodysterol, palmitoyl-carnitine, alpha and gamma bioactive agents, escin, ginkgo biloba and sphingosine.
  • the liporeducing slimming active ingredient can be chosen from: andiroba, Garcinia Cambogia, rutin.
  • the disinfiltrating or veinonic active agents can be chosen from: viburnum, ivy, arnica, pisolle, wild pansy, Fucus vesiculosus, ruscus, ginkgo biloba and escin.
  • Example 1 dietary supplement
  • the food supplement according to Example 1 corresponds to the following weight composition:
  • Table 1 Composition of the dietary supplement
  • the dietary supplement is in the form of a soft capsule.
  • the recommended dose is two capsules a day, preferably one in the morning and one in the evening.
  • the purpose of this test is to demonstrate the effect of the combination as described in Example 1 on the synthesis of type I collagen in a fibroblast model in culture.
  • MATERIALS AND METHODS Normal human dermal fibroblasts were seeded, in PlO passage, in 96-well plate, in DMEM medium (Dulbeco modified Eagle medium) with GlutaMAX TM I, 1000 mg / L D-Glucose, Sodium Pyruvate, added 10% Fetal Calf Serum + antibiotics.
  • DMEM medium Dulbeco modified Eagle medium
  • the cells were rinsed twice with PBS and then incubated for 48 hours with or without the combination according to example 1.
  • the concentration of total intracellular proteins is determined by the method of Lowry and in parallel, the type I collagen released by the cells is assayed in the culture supernatants by an ELISA technique.
  • the concentration of type I collagen is related to the amount of total protein, so the results are expressed in ng of collagen type I per ⁇ g of protein.
  • Example 1 makes it possible, under our experimental conditions, to increase by 481% the synthesis of type I collagen by dermal fibroblasts in culture (p0.001).
  • test will be to evaluate the benefit of supplementation with the dietary supplement according to example 1 in post-delivery body restructuring. It will be analyzed in postpartum women by comparing a treated group with an untreated control group. This test is performed by dermatologists and midwives.
  • Subjects women, lactating or not, having given birth for at least 2 months and at plus 3 months. These women have not followed in parallel another slimming treatment and / or intended to restructure the skin. In addition, they did not receive such treatment after delivery and prior to performing this test.
  • Tables 3 and 4 below show the changes (in%) of the size (Table 3) and thigh (Table 4) for the treated and untreated groups.
  • Table 5 summarizes the results of the subject self-assessments. There is a statistically significant difference between the treatment group and the untreated group in favor of the treatment group. In other words, these results highlight the effectiveness of a bi-daily intake of dietary supplement according to Example 1.

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Animal Behavior & Ethology (AREA)
  • Public Health (AREA)
  • General Health & Medical Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Inorganic Chemistry (AREA)
  • Engineering & Computer Science (AREA)
  • Polymers & Plastics (AREA)
  • Mycology (AREA)
  • Nutrition Science (AREA)
  • Food Science & Technology (AREA)
  • General Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Diabetes (AREA)
  • Dermatology (AREA)
  • Obesity (AREA)
  • Hematology (AREA)
  • Child & Adolescent Psychology (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Coloring Foods And Improving Nutritive Qualities (AREA)
EP06830661A 2005-12-16 2006-12-15 Nahrungsergänzungsmittel auf basis von vitaminen der b-gruppe, spurenelementen und omega-3- und/oder -6-fettsäuren, und verwendung dieses nahrungsergänzungsmittels bei der gleichzeitigen behandlung von lokalisierter cellulite und nachlassen der hautelastizität Withdrawn EP1978827A1 (de)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
FR0512799A FR2894776B1 (fr) 2005-12-16 2005-12-16 Complement alimentaire a base de vitamines du groupe b, d'oligo-elements et d'acides gras en w-3 et/ou w-6 et utilisation de ce complement alimentaire dans le traitement simultane de la cellulite et du relachement cutane localises
PCT/EP2006/069770 WO2007068757A1 (fr) 2005-12-16 2006-12-15 Complément alimentaire à base de vitamines du groupe b, d'oligo-éléments et d'acides gras en w-3 et/ou w-6 et utilisation de ce complément alimentaire dans le traitement simultané de la cellulite et du relachement cutane localises

Publications (1)

Publication Number Publication Date
EP1978827A1 true EP1978827A1 (de) 2008-10-15

Family

ID=36592858

Family Applications (1)

Application Number Title Priority Date Filing Date
EP06830661A Withdrawn EP1978827A1 (de) 2005-12-16 2006-12-15 Nahrungsergänzungsmittel auf basis von vitaminen der b-gruppe, spurenelementen und omega-3- und/oder -6-fettsäuren, und verwendung dieses nahrungsergänzungsmittels bei der gleichzeitigen behandlung von lokalisierter cellulite und nachlassen der hautelastizität

Country Status (4)

Country Link
US (1) US20080292613A1 (de)
EP (1) EP1978827A1 (de)
FR (1) FR2894776B1 (de)
WO (1) WO2007068757A1 (de)

Families Citing this family (3)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US7789901B2 (en) 2007-10-11 2010-09-07 Zimmer Gmbh Bone anchor system
GB2458466A (en) * 2008-03-18 2009-09-23 Kartar Singh Lalvani Composition for hair, skin and nail health maintenance
BR102013013564A2 (pt) 2013-05-31 2015-07-07 Ems Sa Composição para tratamento ou redução de sintomas relacionados à tensão pré-menstrual (tpm), transtorno disfórico pré-menstrual (tdpm), pré-menopausa, menopausa ou desordens hormonais femininas, forma farmacêutica contendo dita composição, processo para produzir dita forma farmacêutica e uso de dita composição

Family Cites Families (9)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN1110910A (zh) * 1994-04-30 1995-11-01 杨龙 一种减肥化妆品及其制造方法
US5656608B1 (en) * 1995-02-23 2000-09-26 Novartis Nutrition Ltd Amino acid compositions and methods of treatment using same
FR2737849B1 (fr) * 1995-08-18 1997-09-19 Boiron Complement nutritionnel absorbable pour l'equilibre quotidien des seniors
JP3607062B2 (ja) * 1997-10-24 2005-01-05 株式会社コーセー 脂肪蓄積抑制剤及びそれを含有する皮膚外用剤
US7153503B1 (en) * 1998-12-19 2006-12-26 Janeel Henderson Comprehensive dietary supplement
DK1155620T3 (da) * 2000-05-18 2005-12-05 Mega Healthcare As Q Kosttilskudsmiddel med vitaminer, mineraler og flerumættede fedtsyrer
FR2829692B1 (fr) * 2001-09-17 2004-10-15 Lehning Lab Composition selective de six categories de substances preservant l'equilibre physiologique chez l'homme comprenant un complexe de micronutriments,un complexe d'antioxydants et un complexe d'acides gras.
US20060280776A1 (en) * 2003-09-02 2006-12-14 Masafumi Koide Diet food
FR2860976B1 (fr) * 2003-10-20 2006-02-10 Ravi Shrivastava Nouvelles compositions synergiques pour ameliorer la biodisponibilite et l'efficacite des acides gras polyinsatures pour le traitement des troubles du fonctionnement cerebral.

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
See references of WO2007068757A1 *

Also Published As

Publication number Publication date
WO2007068757A1 (fr) 2007-06-21
FR2894776B1 (fr) 2008-02-08
US20080292613A1 (en) 2008-11-27
FR2894776A1 (fr) 2007-06-22

Similar Documents

Publication Publication Date Title
AU2008313418B2 (en) Composition for regulating lipid metabolism
FR2694692A1 (fr) Préparation cosmétique de nutrition de la peau.
EP1887890B1 (de) Behandlung von trockenheit des keratingewebes über glyceride
ES2311730T3 (es) Uso de isoflavonas para favorecer el adelgazamiento.
EP1978827A1 (de) Nahrungsergänzungsmittel auf basis von vitaminen der b-gruppe, spurenelementen und omega-3- und/oder -6-fettsäuren, und verwendung dieses nahrungsergänzungsmittels bei der gleichzeitigen behandlung von lokalisierter cellulite und nachlassen der hautelastizität
CA2911394A1 (fr) Utilisation d'acide petroselinique pour lutter contre les desordres esthetiques de la silhouette
FI125743B (fi) Rasvakoostumus iho-ongelmien ehkäisyyn tai hoitoon
RU2245358C2 (ru) Способ получения масла, обогащенного жирными гидроксиоктадекадиеновыми кислотами (hode) или их эфирами, из масляной смеси, содержащей линолевую кислоту или ее эфиры
NZ530554A (en) Neuronutrients
EP1768684A1 (de) Zusammensetzung mit extrakt von blauem lotus mit entspannender wirkung auf die haut
FR2756183A1 (fr) Association d'huile et de peptides d'argan utile pour le traitement des troubles lies au vieillissement cutane
EP1002524B1 (de) Hautalterungsschutzmittel
ITTO20100888A1 (it) Composizioni comprendenti principi attivi di origine vegetale associati o meno a promotori e/o protettori di ossido nitrico per il trattamento e la prevenzione dei deficit erettili e dell'impotenza e per il potenziamento della performance sportiva
FR2948877A1 (fr) Composition pour la protection et la regeneration de la peau
FR2829692A1 (fr) Composition selective de six categories de substances preservant l'equilibre physiologique chez l'homme comprenant un complexe de micronutriments,un complexe d'antioxydants et un complexe d'acides gras.
EP2994092B1 (de) Wirkstoffkombination zur oralen verabreichung zwecks verbesserung der qualität der nägel
FR2916968A1 (fr) Composition cosmetique, dermatologique, alimentaire, nutritionnelle ou pharmaceutique a base de phosphatidylcholine, de cafeine et d'un extrait d'algue.
MX2008007843A (en) Food supplement based on group b vitamins, trace elements and w-3 and/or w-6 fatty acids and use of this food supplement in the simultaneous treatment of localized cellulite and slackening of the skin
WO1994010974A1 (fr) Preparations cosmetiques revitalisant la peau
FR2838645A1 (fr) Nouvelles compositions synergiques de vitamines, de mineraux et d'oligo-elements pour stimuler l'elimination des lipides intracellulaires
US20110306577A1 (en) Topical skin cream comprising phosphatidylcholine dha and l-tyrosine
JP2004269453A (ja) 皮膚化粧料
JPH11322628A (ja) 皮膚外用剤
JP2005060372A (ja) 末梢血行改善用組成物
FR3126870A1 (fr) Composition pharmaceutique ou cosmétique destinée à améliorer la cellulite et les varices caractérisée en ce qu’elle comprend une association de théanine et des polysaccharides issus du matcha.

Legal Events

Date Code Title Description
PUAI Public reference made under article 153(3) epc to a published international application that has entered the european phase

Free format text: ORIGINAL CODE: 0009012

17P Request for examination filed

Effective date: 20080710

AK Designated contracting states

Kind code of ref document: A1

Designated state(s): AT BE BG CH CY CZ DE DK EE ES FI FR GB GR HU IE IS IT LI LT LU LV MC NL PL PT RO SE SI SK TR

17Q First examination report despatched

Effective date: 20081128

REG Reference to a national code

Ref country code: HK

Ref legal event code: DE

Ref document number: 1121345

Country of ref document: HK

GRAP Despatch of communication of intention to grant a patent

Free format text: ORIGINAL CODE: EPIDOSNIGR1

DAX Request for extension of the european patent (deleted)
STAA Information on the status of an ep patent application or granted ep patent

Free format text: STATUS: THE APPLICATION IS DEEMED TO BE WITHDRAWN

18D Application deemed to be withdrawn

Effective date: 20110629

REG Reference to a national code

Ref country code: HK

Ref legal event code: WD

Ref document number: 1121345

Country of ref document: HK